Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.74 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL48250 | 0.95 | SIGMAR1 (0.81) | SIGMAR1HRH3ACHEOPRM1OPRK1 | |
| SCHEMBL47835 | 0.92 | SIGMAR1 (0.76) | SIGMAR1HRH3ACHEOPRM1OPRK1 | |
| Oxalic Acid SCHEMBL47816 | 0.91 | SIGMAR1 (0.72) | SIGMAR1HRH3OPRM1OPRK1KDM4E | |
| Oxalic Acid SCHEMBL47932 | 0.91 | SIGMAR1 (0.72) | SIGMAR1HRH3OPRM1OPRK1KDM4E | |
| Oxalic Acid SCHEMBL47942 | 0.91 | SIGMAR1 (0.72) | SIGMAR1HRH3OPRM1OPRK1KDM4E | |
| Hydrochloric Acid SCHEMBL48116 | 0.91 | SIGMAR1 (0.74) | SIGMAR1HRH3ACHEOPRM1OPRK1 | |
| SCHEMBL48249 | 0.89 | SIGMAR1 (0.85) | SIGMAR1HRH3ACHEOPRM1OPRK1 | |
| Hydrochloric Acid SCHEMBL47919 | 0.88 | SIGMAR1 (0.84) | SIGMAR1HRH3ACHEOPRM1OPRK1 | |
| Oxalic Acid SCHEMBL48295 | 0.87 | SIGMAR1 (0.67) | SIGMAR1HRH3OPRM1OPRK1 | |
| SCHEMBL48044 | 0.86 | SIGMAR1 (0.67) | SIGMAR1HRH3OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43676-E1 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-8129535-B2 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8067406-B2 | Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-11-29 | — | — | US | disclosed |
| US-20110112066-A1 | PREVENTIVE/REMEDY FOR RETINAL NERVE DISEASES CONTAINING ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-05-12 | — | — | US | disclosed |
| US-7897594-B2 | Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-03-01 | — | — | US | disclosed |
| US-20100075941-A1 | PREVENTIVE/REMEDY FOR RETINAL NERVE DISEASES CONTAINING ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-03-25 | — | — | US | disclosed |
| US-20090111992-A1 | ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-04-30 | — | — | US | disclosed |
| US-7468443-B2 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-12-23 | — | — | US | disclosed |
| EP-1437353-B1 | ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2007-06-13 | — | — | EP | disclosed |
| US-20060205709-A1 | Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2006-09-14 | — | — | US | disclosed |
| US-20060194781-A1 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2006-08-31 | — | — | US | disclosed |
| US-7087594-B2 | central nervous system disorders; regenerating nervous systems | TOYAMA CHEMICAL CO., LTD. (JP) | 2006-08-08 | — | — | US | disclosed |
| EP-1614419-A1 | PREVENTIVE/REMEDY FOR RETINAL NERVE DISEASES CONTAINING ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2006-01-11 | — | — | EP | disclosed |
| US-20050070521-A1 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2005-03-31 | — | — | US | disclosed |
| EP-1437353-A1 | ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205709-A1 | Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof | RB1, ALDH1A2, NR2E3 | OPRM1 3166/4885SIGMAR1 2529/4885HRH3 1351/4885 |
| US-20110112066-A1 | PREVENTIVE/REMEDY FOR RETINAL NERVE DISEASES CONTAINING ALKYL ETHER DERIVATIVES OR SALTS THEREOF | RB1, ALDH1A2, NR2E3 | OPRM1 3166/4885SIGMAR1 2529/4885HRH3 1351/4885 |
| US-20060194781-A1 | Alkyl ether derivatives or salts thereof | AHNAK, NGF, PMP22 | OPRM1 1485/4885SIGMAR1 1934/4885HRH3 2125/4885 |
| US-20100075941-A1 | PREVENTIVE/REMEDY FOR RETINAL NERVE DISEASES CONTAINING ALKYL ETHER DERIVATIVES OR SALTS THEREOF | RB1, ALDH1A2, NR2E3 | OPRM1 3166/4885SIGMAR1 2529/4885HRH3 1351/4885 |
| US-20090111992-A1 | ALKYL ETHER DERIVATIVES OR SALTS THEREOF | AHNAK, NGF, PMP22 | OPRM1 1485/4885SIGMAR1 1934/4885HRH3 2125/4885 |
| US-20050070521-A1 | Alkyl ether derivatives or salts thereof | AHNAK, NGF, PMP22 | OPRM1 1485/4885SIGMAR1 1934/4885HRH3 2125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.